

# Prostate-specific *Klf6* Inactivation Impairs Anterior Prostate Branching Morphogenesis through Increased Activation of the Shh Pathway<sup>\*[5]</sup>

Received for publication, April 1, 2009, and in revised form, May 29, 2009 Published, JBC Papers in Press, June 3, 2009, DOI 10.1074/jbc.M109.001776

Ching Ching Leow<sup>†1</sup>, Bu-er Wang<sup>‡</sup>, Jed Ross<sup>§</sup>, Sara M. Chan<sup>¶</sup>, Jiping Zha<sup>¶</sup>, Richard A. D. Carano<sup>§</sup>, Gretchen Frantz<sup>¶</sup>, Michael M. Shen<sup>||</sup>, Frederic J. de Sauvage<sup>‡2</sup>, and Wei-Qiang Gao<sup>‡3</sup>

From the Departments of <sup>†</sup>Molecular Biology, <sup>§</sup>Tumor Biology and Angiogenesis, and <sup>¶</sup>Pathology, Genentech Inc., South San Francisco, California 94080 and the <sup>||</sup>Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York 10032

Krüppel-like factor 6 (*Klf6*) belongs to a family of zinc finger transcription factors known to play a role in development and tumor suppression. Although *Klf6* is highly mutated in prostate cancer, its function in prostate development is unknown. We have generated a prostate-specific *Klf6*-deficient mouse model and report here a novel role for *Klf6* in the regulation of prostate branching morphogenesis. Importantly, our study reveals a novel relationship between *Klf6* and the Shh pathway. *Klf6*-deficiency leads to elevated levels of hedgehog pathway components (Shh, Ptc, and Gli) and loss of their localized expression, which in turn causes impaired lateral branching.

*Klf6* belongs to the family of Krüppel-like zinc finger transcription factors that regulate cell proliferation and differentiation (1). All members of the *Klf* gene family contain a highly conserved zinc finger DNA binding domain at their C terminus and an activation domain at its N terminus, distinct to each *Klf* gene and accounting for their wide-ranging biological capabilities (2–4). Similar to other members of the *Klf* family (5, 6), *Klf6* is reported to act as a tumor suppressor (7–10). *Klf6* has been reported to be mutated in a large percentage of human prostate tumors (7), but its function during normal development has not been elucidated.

Prostate development, specifically epithelial branching morphogenesis, is a well studied process. Outgrowth and branching of the prostate epithelial buds into the enveloping mesenchyme occur during the first 3 weeks postnatally (11). The fully developed prostate in an adult mouse is composed of three different paired lobes, referred as the anterior, ventral, and dorsal-lateral lobes. In addition, the number of main ducts and complexity of ductal branching vary among the three lobes. A number of growth factors/pathways have been implicated in regulating

prostatic epithelial proliferation and differentiation, including hedgehog (Hh),<sup>4</sup> bone morphogenic proteins (BMPs), fibroblastic growth factors (FGFs), and Notch and Wnt pathways (12–19). For example, work done in our laboratory and others showed that sonic hedgehog (Shh) produced in the prostatic epithelium is a negative regulator of prostatic branching morphogenesis, mediated indirectly by periepithelial mesenchymal cells (12–15). In addition, while mesenchymal FGF10 stimulates prostatic epithelial growth (16), BMP4 is a mesenchymal factor that inhibits prostatic ductal budding and branching morphogenesis (17).

All *Klf* knockouts generated thus far are embryonic lethal (20–22), including the *Klf6* knock-out mice (23). Because prostate development begins in late gestation and continues postnatally, we overcame embryonic lethality to study the role of *Klf6* in prostate development and tumorigenesis by generating a prostate-specific deletion of the *Klf6* gene using a Cre-lox recombination approach. We report here a novel role for *Klf6* in the regulation of Shh-mediated epithelial branching morphogenesis in the anterior prostate.

## MATERIALS AND METHODS

**Generation, Genotyping, and Reverse Transcription-PCR of *Klf6* Prostate-specific Mutant Mice**—We generated prostate-specific deletion of *Klf6* exons 2 and 3 by crossing *Klf6*<sup>fl/fl</sup> mice (C57BL/6, 129Sv) with *Nkx3.1*<sup>Cre/+</sup> (C57BL/6, 129Sv) knock-in mice, which expressed Cre recombinase from the *Nkx3.1* locus.<sup>5</sup> The *Nkx3.1*<sup>Cre/+</sup> knock-in mice used in the crosses were phenotypically identical to the published *Nkx3.1* mutant mice (25) and, thus, exhibited normal prostate development. PIN lesions were detected in *Nkx3.1*<sup>Cre/+</sup> mice only after they have been aged beyond 1 year.<sup>6</sup> Data presented in this report were mostly analyzed at P5, and the latest time point presented is 1 year of age, where loss of one *Nkx3.1* allele did not exert any abnormal effects on prostate development. Genotyping of *Klf6* mutants was done by Southern analysis for the *F*<sub>0</sub> and *F*<sub>1</sub> gen-

\* This work was supported, in part, by National Institutes of Health Grant CA115985 (to M. M. S.).

[5] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Figs. S1–S3.

<sup>1</sup> Present address: MedImmune, One MedImmune Way, Gaithersburg, MD 20878.

<sup>2</sup> To whom correspondence may be addressed: MS#37, 1 DNA Way, South San Francisco, CA 94080. Fax: 650-225-6412; E-mail: [sauvage@gene.com](mailto:sauvage@gene.com).

<sup>3</sup> To whom correspondence may be addressed: MS#37, 1 DNA Way, South San Francisco, CA 94080. Tel.: 650-225-8101; Fax: 650-225-6412; E-mail: [gao@gene.com](mailto:gao@gene.com).

<sup>4</sup> The abbreviations used are: Hh, hedgehog; BMP, bone morphogenic protein; FGF, fibroblastic growth factor; Shh, sonic hedgehog; Micro-CT, micro-computed tomography; SMA, smooth muscle actin; H&E, hematoxylin and eosin; TCRD, T-cell receptor delta chain.

<sup>5</sup> Y. P. Hu, S. M. Price, Z. Chen, W. Banach-Petrosky, C. Abate-Shen, and M. M. Shen, unpublished observations.

<sup>6</sup> M. Shen, unpublished data.

## Role of *Klf6* in Branching Morphogenesis

erations (data not shown), and subsequent generations were genotyped by PCR analysis using the forward primer, 5'-GTC TCT TGA CAC CTT GAC TAT CTC TCC-3', and the reverse primer, 5'-CTA CAG GAT TCG TCC CTC TGC-3', from genomic DNA obtained from tail biopsies. We prepared RNA from TRIzol (Invitrogen) extractions from various prostate lobes, brain, testes, and kidney tissues. The RNA was then used for reverse transcription-PCR to confirm *Klf6* deletion through detection of a 695-bp PCR product using forward primer 5'-GAA TAC TCT TGG AGT GCT AGG and reverse primer 5'-CTG CTC CTT CAG AGG TGC. RNA loading control was performed by employing a housekeeping gene called T-cell receptor delta chain (TCRD). TCRD was employed to ensure that equal RNA was loaded into each lane and was detected using forward primer 5'-CAA ATG TTG CTT GTC TGG TG and reverse primer 5'-GTC AGT CGA GTG CAC AGT TT. In addition, the *Ptc-lacZ* reporter mice, also known as *Ptch1*<sup>D11</sup> (26), were obtained from Cruris Inc. They were intercrossed with *Nkx3.1Cre;Klf6*<sup>fl/fl</sup> to produce the experimental cohorts. Mice were genotyped by PCR.

**Prostate Microdissection, *ex Vivo* Three-dimensional Ultrasound, and *ex Vivo* Micro-CT**—Prostates were harvested and treated with 1% collagenase (Sigma) for 15 min at 37 °C. Individual ducts were teased apart using forceps (11). A Leica Z6 APO microscope was used to acquire images of the microdissected prostates. Tissues were fixed in 4% paraformaldehyde. High resolution ultrasound imaging was employed to evaluate the interior of anterior prostate. The fixed tissue samples were placed in a bath of phosphate-buffered saline to provide acoustic coupling for *ex vivo* three-dimensional ultrasound micro-imaging. Ultrasound imaging was performed with a high resolution dedicated small animal ultrasound imaging system (Vevo 770, VisualSonics, Toronto, Canada). Images were acquired with a single-element (mechanical sweep) ultrasound transducer operating at a center frequency of 55 MHz and a 4.5 mm focal length, resulting in an axial resolution of 30  $\mu$ m and a lateral resolution of 50  $\mu$ m. Three-dimensional acquisition was performed by the linear translation of the transducer that was controlled by a motorized drive mechanism, where images were acquired every 50  $\mu$ m to provide a three-dimensional field-of-view of 7  $\times$  7  $\times$  10 mm. Images were processed with image analysis software provide with the Vevo 770 imaging.


Micro-CT was used to provide a quantitative analysis of the number of ductal tips and branch points. Microdissected tissues were soaked in 5% Isovue®/phosphate-buffered saline contrast agent for 2 h, blotted onto paper, and then suspended in soybean oil, which provides homogeneous and low x-ray absorption background for *ex vivo* micro-CT imaging. Samples were then imaged with the Scanco  $\mu$ CT40 (Bassendorf, Switzerland) micro-CT system at an isotropic voxel size of 12  $\mu$ m. Images were acquired with the x-ray tube operating at an energy level of 45 kV and a current of 177 microamperes with an integration time of 300 ms. Acquired images were then analyzed using image analysis software from AnalyzeDirect (Lenexa, KS).

**Histologic, Immunofluorescent Staining, and *in Situ* Hybridization Methods**—We harvested prostate tissues from various genotypes and stages of development. Tissues for hematoxylin and eosin (H&E) histological staining purposes were formalin-fixed and paraffin embedded. Tissues were then sectioned and stained with H&E. Tissues for immunofluorescent staining were fixed in 4% paraformaldehyde/phosphate-buffered saline prior to Declere antigen retrieval (Cell Marque) using a pressure cooker for 10 min and then blocked in 10% donkey serum/phosphate-buffered saline. Primary antibodies used include rabbit anti-*Klf6* (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-Ki67 (LabVision), rabbit anti- $\beta$ -galactosidase (1:10,000, MP Biomedical, without antigen retrieval) (19), rabbit anti-androgen receptor (Upstate), rabbit anti-smooth muscle actin (LabVision), rabbit anti-desmin (EuroDiagnostica), rabbit anti-ck14 (Covance), mouse anti-ck8 (Novus), rabbit anti-phospho-Smad1/5/8 (1:500, Cell Signaling), and mouse anti-E-cadherin (BD Pharmingen). Secondary antibodies used to detect respective primary antibodies were anti-rabbit Alexa 488 (Invitrogen) and anti-mouse Alexa 594 (Invitrogen). Respective IgG controls were used on serial sections placed on each slide. Sections were mounted using Fluoromount containing 4',6-diamidino-2-phenylindole stain (Dako).

Prostate tissues for non-radioactive *in situ* hybridization were harvested and fixed in 4% paraformaldehyde prior to embedding in an OCT compound and freezing on dry ice. Pretreatment of frozen tissue sections included proteinase K digestion (40  $\mu$ g/ml, 6 min, and 25 °C) and acetylation (0.1 M triethanolamine, pH 8.0, 0.25% acetic anhydride, 10 min, 25 °C). Sections were hybridized with Riboprobes against *Shh*, *Ptc*, and *Gli1* at 60 °C overnight, washed sequentially with 2 $\times$  SSC, 1 $\times$  SSC, 0.5 $\times$  SSC, and blocked with 1 $\times$  Digoxygenin-Block (Roche Applied Science) for 1 h before hybridization with alkaline phosphatase conjugated anti-Dig antibody (Roche Applied Science) for 1 h at room temperature.

Radioactive *in situ* hybridization was performed as previously described (27). PCR primers were designed to amplify a 415-bp fragment of mouse BMP4 spanning from nucleotides 948 to 1362 of mouse BMP4 reference sequence NM\_007554.2 (upper, 5'-CAGGGCTTCCACCGTATAAAC-3'; lower, 5'-AATGGCGACGGCAGTT-3'). Primers included extensions encoding 27-nucleotide T7 or T3 RNA polymerase initiation sites to allow *in vitro* transcription of sense or antisense probes, respectively, from the amplified products.

Formalin-fixed, paraffin-embedded sections 5- $\mu$ m thick were deparaffinized, deproteinized in 10  $\mu$ g/ml Proteinase K for 30 min at 37 °C, and further processed for *in situ* hybridization as previously described (Jubb *et al.* (27)). [<sup>33</sup>P]UTP-labeled sense and antisense probes were hybridized to the sections at 55 °C overnight. Unhybridized probe was removed by incubation in 20  $\mu$ g/ml RNase A for 30 min at 37 °C, followed by a high stringency wash at 55 °C in 0.1  $\times$  SSC for 2 h and dehydration through graded ethanols. The slides were dipped in NTB nuclear track emulsion (Eastman Kodak), exposed in sealed plastic slide boxes containing desiccant for 4 weeks at 4 °C, developed, and counterstained with H&E. Images were analyzed in Metamorph (version 7.0r4, MDS Analytical, Sunnyvale, CA). Briefly, regions of interest (epithelial ductal units)



**FIGURE 1. *Klf6* expression and generation of mutant mice with prostate-specific *Klf6* deletion.** *A* and *B*, immunofluorescent staining of P4 and adult prostate, respectively, with anti-*Klf6* revealed that nuclear *Klf6* was expressed exclusively in the epithelial cells at both stages of development (arrow, *A* and *B*). Stromal staining was nonspecific and present in the anti-rabbit IgG control. *C*, a schematic drawing of the *Klf6* wildtype (*wt*) genomic locus, targeting vector, *Klf6* floxed mutant allele (*Klf6<sup>fl/fl</sup>*) and *Klf6* deleted allele upon *Nkx3.1*-driven Cre recombinase-mediated deletion. The targeting vector was generated by inserting two loxP sites flanking a *neo* cassette between exons 1 and 2 and a loxP site just upstream of exon 3. Cre recombination would result in the excision of exons 2 and 3. *D*, genotyping of *Klf6* mutant mice by PCR analysis. PCR of genomic DNA from wild-type mice would yield a 412-bp band, and the *Klf6<sup>fl/fl</sup>* mice would yield a 448-bp PCR product due to the presence of a loxP site. *E*, reverse transcription-PCR analysis of mRNA obtained from anterior (AP), dorsolateral (DLP), and ventral (VP) prostate of *Klf6<sup>fl/fl</sup>* mice with and without Cre-recombinase and from the brain, testis, and kidney of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* tissues. Deletion of exons 2 and 3 from *Klf6* would yield a 695-bp PCR product with the forward and reverse primer pair and equal loading was observed in all lanes through detection of a 220-bp PCR product of the *TCRD* gene. Bar, 50  $\mu$ m for *A* and *B*.

were created manually to restrict analysis to the lumen. A threshold value was applied for each set of images (~95% of maximum pixel value) to identify positively stained areas. The

total area of each region and the positive stained area for each region were outputted directly to Excel (Microsoft, Redmond, WA). A value of 10.3 pixels per silver grain was used to calculate the total number of silver grains associated with the positively stained area.


## RESULTS

**Generation of Mice with Prostate-specific Deletion of *Klf6***—To understand the developmental role of *Klf6* in the prostate, we first defined the spatial and temporal expression pattern of *Klf6*. Anti-*Klf6* immunofluorescent staining revealed that *Klf6* expression was highly expressed in the nuclei of prostate epithelium as early as postnatal day 1 (P1) (data not shown), P4 (arrow, Fig. 1*A*), and mature prostate (arrow, Fig. 1*B*). The specificity of the anti-*Klf6* antibody was confirmed by the lack of immunofluorescent staining in the nuclei of cells in which the *Klf6* were deleted (see below, Fig. 2, *N* and *P*).

To generate a prostate-specific deletion of exons 2 and 3 that encompass all three zinc fingers, which inactivates *Klf6* transcription factor activity (Fig. 1*C*), we crossed *Klf6* conditional mutant mice containing loxP sites flanking exons 2 and 3 (*Klf6<sup>fl/fl</sup>*) with *Nkx3.1<sup>Cre/+</sup>* knock-in mice in which the *Nkx3.1* promoter directs expression of Cre-recombinase to the prostate epithelium.<sup>5</sup> To demonstrate prostate-specific deletion of exons 2 and 3 from *Klf6*, we performed reverse transcription-PCR analysis on mRNA from various genotypes and tissues. A 695-bp PCR product, amplified when exons 2 and 3 were deleted, could only be detected in *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostate but not in brain, testes, and kidney or *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* prostate. The highest level of Cre-mediated deletion of *Klf6* was detected in the anterior prostate (Fig. 1*E*).

**Branching and Canalization Defects in *Klf6*-deficient Prostate**—Progression of prostate branching morphogenesis varies from lobe to lobe. Main ducts are present in all lobes at birth, but lateral branching in the ventral prostates begins at birth (P1), the ante-

## Role of *Klf6* in Branching Morphogenesis




**FIGURE 2. Abnormality in ductal branching in the *Klf6*-deficient prostate epithelium.** Morphological ductal aberrations in *Klf6*-deficient anterior prostates were first observed at P5 and retained in adult mice. Light microscopy images (A, B, E, and F) and H&E staining (C and D) of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* (A, C, and E) and *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* (B, D, and F) from P5 and 1-year-old anterior prostates that were microdissected prior to imaging. Only one side of the symmetrical anterior lobe was imaged, and three mice were imaged from each stage. Branching was visible in both microdissected (arrow, A) and H&E-stained (arrow, C) P5 sections from *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* but not in *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* (B and D). *Ex vivo* ultrasound imaging allowed visualization of the interior of anterior prostate of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* (G) that appears dense and white due to extensive epithelial infolding in the ducts, and the single layer of white epithelial lumen that outlines the main ducts of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* mice (H). Arrowhead (in H) points to the significantly enhanced luminal space present within the main duct of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* anterior prostate. H&E staining of prostates obtained from 6-month-old (I and K) *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* and (J and L) *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* mice. Note that the widest region at the base of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* prostate (K) fits into the field of view, whereas the narrowest region of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostate (L) does not fit into the field of view. Epithelial infolding that spans the lumen was more extensive in *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* prostates (arrow, I) than *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostates (arrow, J). Insets represent higher magnification of the regions marked by the dotted square in K and L, respectively, that revealed nuclei with normal characteristics. Immunofluorescent staining of *Klf6* expression in prostate tissues obtained from 8-week-old *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* (M and O) and *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* (N and P) mice. *Klf6*, which is a transcription factor, was highly localized to the nuclei of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* prostate epithelium (arrows, O), and depletion of *Klf6* in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostate was confirmed by the absence of green signal in the nuclei (arrowhead, P). I, J, M, and N, low magnification and high magnification (K, L, O, and P) of respective images. Bar in A, 500  $\mu$ m for A and B, 1000  $\mu$ m for E and F, and 750  $\mu$ m for G and H. Bar in C, 50  $\mu$ m for C and D. Bar in K, 200  $\mu$ m for I and J and 100  $\mu$ m for K–N. Bar in O, 50  $\mu$ m for O and P.

rior prostate at P5, and the dorsolateral prostate by P10 (11, 28). Gross examination of all three lobes of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostates revealed a prominent branching phenotype primarily in the anterior prostate, which was consistent with the highest level of *Klf6* depletion. The branching defect in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* anterior prostates was evident as early as postnatal day 5 (P5) (Fig. 2, B and D). Impaired branching was 100% penetrant in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* mice, whereas all *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>*, *Klf6<sup>fl/+</sup>Nkx3.1<sup>Cre/+</sup>*, and *Klf6<sup>+/+</sup>Nkx3.1<sup>Cre/+</sup>* prostates developed normally. To rule out a possi-

bility of a delay in secondary branching, we examined *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostates from 6-month-old (data not shown) and 1-year-old (Fig. 2F) mice and found that those mature prostates were still without secondary branches as first noted at P5. This was in contrast to the extensive secondary and tertiary branching observed in 1-year-old *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* mice (Fig. 2E). Distinguishing branching features in the dorsal and ventral prostates were not as apparent between *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* and *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* except for larger luminal spaces in the ducts (supplemental Fig. S1, A–D). This milder phenotype could be due to less efficient *Klf6* deletion in those lobes, because the greatest level of *Klf6* deletion was primarily in the anterior lobe, the remainder of our analyses focused therefore on detailed characterization of the anterior prostate.

Canalization of the anterior prostate begins around P2 and progresses in a proximal to distal manner with elaboration of epithelial infolding or tufting within the luminal space (28, 29). A novel *ex vivo* application of three-dimensional, high resolution ultrasound micro-imaging technology was employed to visualize the luminal space of intricately microdissected prostates. Extensive epithelial infolding in the smaller luminal space of 1-year-old *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* anterior prostates resulted in a dense, white, hyperechoic regions within the ultrasound image (Fig. 2G), which were also visible by H&E staining (Fig. 2, I and K). The absence of secondary branching from the two main ducts was evident in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* anterior prostates (Fig. 2H). *Ex vivo* ultrasound imaging revealed a dark, hypoechoic luminal space in the main ducts, suggesting that canalization was unaffected (arrowhead, Fig. 2H). The epithelial infolding in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* anterior prostate was significantly reduced resulting in a defined layer of epithelial cells outlining the main ducts (Fig. 2H). H&E-stained sections also revealed that the epithelial infolding rarely spanned across the lumen, and the eosinophilic lumen suggests a functional epithelium, capable of secretion (Fig. 2, J and L). Further histopathological analysis of the H&E-stained *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* sections did not reveal any signs of hyperproliferation, nuclear anomalies, or mitotic figures (insets, Fig. 2, J and L). Given the normal appearance of the luminal epithelium, we performed anti-*Klf6* immunofluorescent staining to confirm that *Klf6* protein was indeed depleted in the prostate epithelium. In *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* mice, nuclear *Klf6* expression was detected in the prostate epithelium (arrow, Fig. 2O), whereas positive nuclear staining was absent from *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* epithelium (arrowhead, Fig. 2P).


To quantify the number of ductal tips and branch points we used *ex vivo* micro-CT to image the anterior prostate. It was necessary to microdissect away connective tissues encapsulating the prostate to reveal adequately separated ducts ideal for micro-CT imaging. We found significantly ( $p < 0.001$ ) more ductal tips (red dot) and branch points (red Y) in the anterior prostate of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* mice (Fig. 3, A, C, and E) than *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* mice (Fig. 3, B, D, and F). It should be pointed out that, although *Nkx3.1* null mice show a defect in prostatic branching morphogenesis (25, 30), the ductal epithelium in *Nkx3.1<sup>+/-</sup>* mice is essentially indistinguishable from wild type at 2 months of age and only shows much milder phenotype than that in *Nkx3.1<sup>-/-</sup>* mice at an age of 10–12 months



**FIGURE 3. Impaired lateral branching in *Klf6*-deficient anterior prostates.** Microdissected prostate from *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup> (A and C) and *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup> (B and D) mice were imaged using *ex vivo* micro-CT and three-dimensional images were reconstructed. Ductal tips (A and B) and branch points (C and D) were marked on the three-dimensional images, counted ( $n = 4$  from each genotype) and plotted in bar graphs, respectively (E and F). The number of ductal tips and branch points sprouting out of the main ducts are significantly more in (A, C, and E) *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup> than (B, D, and F) *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup> prostates. Statistical significance was calculated using Student's *t* test, and the bars represent mean  $\pm$  S.E. Bar, 1 mm for A–D.

or older (Fig. 4E of (30)). The branching defect due to conditional *Klf6* deletion reported in the present study is far more severe than that found even in *Nkx3.1* homozygous knockouts (Figs. 2F and 3 of the present study, as compared with Fig. 4 (I and J) of Ref. 25). These findings together argue strongly that *Klf6* inactivation makes important contribution to the defect in prostate branching morphogenesis.

**Characterization of Gene Expression in Abnormal Prostate Resulting from Loss of *Klf6***—Murine prostate development begins in late gestation, in a process involving reciprocal interactions between the prostate epithelium and mesenchyme (31, 32). During development, the mesenchyme condenses around



**FIGURE 4. Smooth muscle formed along the sides of *Klf6*-deficient main ducts of the anterior prostate without intermittent smooth muscle deficient areas to permit lateral branching.** Immunofluorescent staining of P5 *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup> anterior prostates showed similar expression of early smooth muscle marker, SMA and late marker (A and C), desmin lining the ducts (E and G) but absent in areas where new lateral branches were formed (arrow). In *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup> anterior prostates, SMA (B and D) and desmin (F and H) were expressed continuously along the entire length of the main ducts except for the distal tip (arrowhead). Low magnification (A, B, E, and F) and high magnification (C, D, G, and H) of respective images. Bar, 100  $\mu$ m for A, B, E, and F, and 50  $\mu$ m for C, D, G, and H.


the ducts in a proximal to distal fashion to encase the ducts with smooth muscle actin (SMA), the earliest smooth muscle marker expressed, and desmin, a later marker (33). To determine the state of smooth muscle differentiation, we examined the expression of SMA and desmin at P5, which corresponds to the initiation of secondary branching in the anterior prostate. We found SMA (Fig. 4, A and C) and desmin (Fig. 4, E and G) expressed proximally but not at the distal tips (arrow) of newly branched lateral ducts of *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup> prostates. In contrast, SMA (Fig. 4, B and D) and desmin (Fig. 4, F and H) were expressed along the entire length of each main duct of *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup>, but not at the distal tip (arrowhead). Interestingly, this is consistent with previous findings where the relative thickness of the smooth muscle layer is inversely proportional to epithelial ductal growth (34). This suggests that, although there was diminished smooth muscle expression around the

## Role of *Klf6* in Branching Morphogenesis

emerging lateral ducts of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* prostates, lateral epithelial branching in *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* was prevented as a result of a continuous layer of smooth muscle along the main ducts. On the other hand, it is also possible that the continuous layer of smooth muscle formed around the main ducts as a result of the absence of branching. To further understand this branching defect, we examined expression of androgen receptor by immunofluorescent staining, because several investigators had demonstrated that postnatal prostate branching morphogenesis and differentiation of the stroma are highly regulated by androgen (32, 33, 35). Androgen receptor was expressed continuously around the primary and secondary ducts of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* (supplemental Fig. S2, A and C) and the main ducts of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostates (supplemental Fig. S2, B and D). There were no apparent differences in proliferation by anti-Ki67 staining (supplemental Fig. S3, A and B), cell death by anti-active caspase-3 (data not shown) and epithelial differentiation by anti-CK8, anti-CK14 and anti-E-cadherin staining (supplemental Figs. S2 (E–H) and S3 (C and D)). Therefore, the lack of lateral branching could not be attributed to androgen receptor expression, proliferation, cell death, or epithelial differentiation in the mutant mice.

Factors in the epithelium and mesenchyme essential for proper ductal branching include *Nkx3.1*, *Hh*, *BMP*, *FGF*, *Notch*, and *Wnt* pathway components (12–19, 25, 36). Our group and others have previously shown that the activated *Shh* pathway could inhibit prostatic ductal branching (12–15, 37). The lack of branching in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostates prompted us to examine mRNA expression of *Shh* pathway components by *in situ* hybridization. In *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* prostates, highly localized epithelial *Shh* expression was detected in the distal tips, which was consistent with a previous reported study (37) (arrow, Fig. 5, A and C). However, *Shh* expression was dispersed throughout the entire length of the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* main ducts (Fig. 5, B and D). Similarly, intense and dispersed expression of *Ptc* and *Gli1*, two well validated *Hh* target genes (38, 39), were detected throughout the stroma surrounding the main ducts of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* (arrowhead, Fig. 5, F and J). This was in sharp contrast to the highly localized expression of *Ptc* and *Gli1* observed in the stroma adjacent to *Shh* expression in the ductal tips of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* that was previously shown in wild-type prostates (37) (arrow, Fig. 5, E, G, I, and K).


To confirm the change in expression pattern of *Ptc*, we crossed *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* with *Ptc-lacZ* reporter mice (26) in which *lacZ* is driven under the *Ptc* promoter, to obtain *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>;Ptc-lacZ* mice. This *Ptc-lacZ* reporter line is a well characterized and a sensitive indicator of endogenous *Ptc* expression or *Hh* signaling activity (26). Consistent with the *in situ* hybridization results, we found that there was increased  $\beta$ -galactosidase staining in the periepipithelial stroma of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>;Ptc-lacZ* mice compared with the staining observed in *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>;Ptc-lacZ* mice (Fig. 6). There were multiple cell layers of  $\beta$ -galactosidase-positive cells surrounding the epithelium in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>;Ptc-lacZ* mice (Fig. 6, A and C). In sharp contrast, only one to two layers of  $\beta$ -galactosidase-positive cells were seen in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>;Ptc-lacZ* control littermates (Fig. 6, B and D). Together these



**FIGURE 5. Enhanced expression of *Shh* pathway components in *Klf6*-deficient prostate.** *In situ* hybridization analysis of P7 *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* prostates revealed expression of *Shh* in the epithelium at the tips of lateral branches (arrow, A). *Shh* expression was elevated and dispersed throughout the main ductal epithelium of *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostates (arrowhead, B). Localized *Ptc* (arrow, E and G) and *Gli1* (arrow, I and K) expression in *Klf6<sup>fl/fl</sup>Nkx3.1<sup>+/+</sup>* prostates were detected in the stromal region immediately adjacent to the *Shh* expressing epithelium at the ductal tips. However, in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* prostates, *Ptc* (arrowhead, F and H) and *Gli1* (arrowhead, J and L) expression were highly elevated and localized expression to the stroma at the ductal tips was lost. Instead, *Ptc* and *Gli1* expression were dispersed throughout the perimeter of the main ducts (arrowhead, F, H, J, and L). Low magnification (A, B, E, F, I, and G) and high magnification (C, D, G, H, K, and L) of respective images. Bars: 100  $\mu$ m for A, B, E, F, I, and G, and 50  $\mu$ m for C, D, G, H, and K.

findings indicate that *Klf6* expression leads to broader expression of *Hh* signaling around the developing prostate ducts.

In an attempt to further understand how epithelial branching morphogenesis is inhibited in the *Klf6<sup>fl/fl</sup>Nkx3.1<sup>Cre/+</sup>* mice, we also performed radioactive *in situ* hybridization using a probe specific for *BMP4*, which was previously shown to be expressed in the prostatic stroma and can inhibit prostatic epithelial duc-



**FIGURE 6.  $\beta$ -Galactosidase expression in *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup>;*Ptc-lacZ* reporter mouse prostates.** Immunostaining of prostate tissue sections prepared from P7 *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup>;*Ptc-lacZ* (A and C) and *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup>;*Ptc-lacZ* (B and D) mice with anti- $\beta$ -galactosidase antibody. The sections were counterstaining with 4',6-diamidino-2-phenylindole (blue). Note that  $\beta$ -galactosidase-expressing cells are located in the mesenchymal cells surrounding the epithelium. Although there were multiple cell layers of  $\beta$ -galactosidase positive cells in the *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup>;*Ptc-lacZ* mice (A and C), only one to two layers of  $\beta$ -galactosidase-positive cells were seen in the *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup>;*Ptc-lacZ* control littermates. Slides were viewed using a Zeiss Axiophot epifluorescence microscope. Images were captured with Compix imaging systems using a cooled RGB charge-coupled device camera and analyzed using Adobe Photoshop CS. Bar, 50  $\mu$ m.

tal budding and branching morphogenesis (17). As shown in Fig. 7, which contains tangential sections of P7 prostates, overall expression of BMP4 in the stroma surrounding the epithelium was enhanced in *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup> mice (Fig. 7, A–D) compared with the expression levels observed in sections taken from *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup> mice (Fig. 7, E–H). Upon quantification of the silver grains from the *in situ* hybridization, there was more than 4-fold BMP4 expression in the *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup> mice as compared with the *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup> mice ( $p < 0.05$ , Fig. 7I). Next, we investigated the status of signaling downstream of BMP4 by examining the phosphorylation status of Smad1/5/8. Immunofluorescence staining using anti-phospho-Smad1/5/8 antibody revealed enhanced nuclear staining in the prostate sections from *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup> mice, whereas there were only a few positively stained nuclei in the *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>+/+</sup> sections (Fig. 7, J and K). These findings together suggest that up-regulation of Hh signaling induced by the deletion of the *Klf6* gene may inhibit prostate epithelial branching via up-regulation of BMP4.

## DISCUSSION


The *Klf* gene family is known to be crucial for development in vertebrates (4). They are expressed in a large number of tissues (40) and play an important role in the control of hematopoietic cell differentiation (4), erythroid cell maturation (21, 41), T-cell activation (42), blood vessel stability (20), and skin permeability (22). Using the prostate as a model, we describe here for the first time a role for *Klf6* in prostate branching morphogenesis. Consistent with this notion, *Klf14*, another *Klf* family member, has been shown to be critical for alveolarization in the developing

lung. Deletion of *Klf14* leads to thinner lung alveolar walls and poor outgrowth of secondary septa, which results in defective blood-air exchange and respiratory failures in newborn mice (43). In the kidney, *Klf6* is known to be expressed in the Wolfian duct, uterine bud, collecting ducts, and mesangium (44), an expression profile that would also be consistent with a role in branching morphogenesis.

Because systemic loss of *Klf6* is embryonic lethal (23), we generated mice deficient for *Klf6* specifically in the prostate. The resulting lateral branching defect in *Klf6*-deficient prostate was confirmed by light microscopy, H&E staining, and micro-CT imaging. Using a novel *ex vivo* ultrasound imaging modality, we were able to demonstrate that *Klf6* plays a role in modulating the epithelial infolding and tufting, which results in decreased surface area of functional epithelium. The most prominent branching defects are seen in the anterior prostate, also known as a coagulating gland, which correlates with the highest level of *Klf6* depletion (Fig. 1E). Despite the reduction in epithelial infolding and tufting whether or not prostatic function has been impaired in these mice remains to be determined.

The augmented branching defect in the anterior prostate is noteworthy, because the branching patterns in the anterior prostate are distinct from the dorsolateral prostate and ventral prostate. In addition, the embryologic origin of the anterior prostate is also different from the other prostate lobes (45, 46). Although branching patterns of the ventral prostate and dorsolateral prostates are believed to arise from the urogenital sinus epithelium invaginating into urogenital sinus mesenchyme, the anterior prostate is thought to be derived from urogenital sinus epithelium at the most dorsal aspect of the urogenital sinus invaginating into the mesenchyme of the seminal vesicle, which itself is derived from the mesodermal Wolfian duct. Hence, the resulting branched structure in the anterior prostate has unique patterns distinct from the other prostate lobes and occurs as a result of lateral branch events and not as a result of bifurcations at the elongating tips.

Consistent with previous reports from our group and others on the role of Shh signaling in prostate branching (12–15, 37), both *Ptc-lacZ* reporter mice crossed to *Klf6*<sup>f/f</sup>*Nkx3.1*<sup>Cre/+</sup> mice and *in situ* hybridization data in the present study indicate that impaired lateral branching in the *Klf6*-deficient prostate correlate with an up-regulation and loss of spatial localization of Shh, *Ptc*, and *Gli1*. Further support for the involvement of focal Hh signaling in prostate epithelial branching comes from a study by Bushman and co-workers (15), showing a close association between prostate ductal bud formation and localized expression of Shh at the growing tips of elongating prostate ducts. In addition, Shh regulates prostate branching morphogenesis in concert with FGF10 and BMP4 (37). Shh secreted from the epithelial ductal tips can down-regulate FGF10 that stimulates epithelial cell growth (16) and/or up-regulate BMP4 that inhibits epithelial cell growth (17) in the mesenchyme, which results in epithelial ductal branching (37). In the present study, we show that loss of *Klf6* leads to dispersed, rather than focal, Shh expression throughout the epithelial ducts and corresponding dispersed *Ptc* and *Gli1* expression in the adjacent mesenchyme (Fig. 5). This broader domain of Hh pathway activity leads to an up-regulation of BMP4 expres-



**FIGURE 7. Expression of BMP4 is up-regulated in *Klf6<sup>f/f</sup>Nkx3.1<sup>Cre/+</sup>* mice.** *A* and *B*, BMP4 expression detected by radioactive *in situ* hybridization in P7 *Klf6<sup>f/f</sup>Nkx3.1<sup>Cre/+</sup>* prostates. *C* and *D*, H&E staining from the same field of *A* and *B*. *E* and *F*, BMP4 expression in P7 *Klf6<sup>f/f</sup>Nkx3.1<sup>+/+</sup>* prostates. *G* and *H*, H&E staining from the same field of *E* and *F*. Note that the BMP4 signal is stronger and broader in the mutants compared with the control mice (*arrows* in *A* and *B* versus *arrowheads* in *E* and *F*). *I*, MetaMorph analysis of numbers of silver grains per  $\mu\text{m}^2$  indicates a significant increase in the prostate of *Klf6<sup>f/f</sup>Nkx3.1<sup>Cre/+</sup>* mice as compared with that of *Klf6<sup>f/f</sup>Nkx3.1<sup>+/+</sup>* mice. Sense control probes revealed no hybridization signal above background (not shown). *J* and *K*, phospho-Smad1/5/8 immunostaining of P7 prostates from *Klf6<sup>f/f</sup>Nkx3.1<sup>Cre/+</sup>* and *Klf6<sup>f/f</sup>Nkx3.1<sup>+/+</sup>* mice. Note that the staining is stronger, and the number of phospho-Smad1/5/8-positive nuclei is higher in the *Klf6<sup>f/f</sup>Nkx3.1<sup>Cre/+</sup>* prostate (*yellow arrows* in *J*) than the *Klf6<sup>f/f</sup>Nkx3.1<sup>+/+</sup>* prostate (*yellow arrowheads* in *K*). Bar in *G*, 100  $\mu\text{m}$  for *A*–*H*; bar in *K*, 100  $\mu\text{m}$  for *J* and *K*.

sion, resulting in reduced ductal branching. As proposed by Pu and coworkers, the interplay and localized expression pattern of *Shh* and *BMP4* are key to conveying critical branching information (37).

*Klf6* is reported to be a tumor suppressor that is inactivated in a large subset of prostate cancer (47). However, our detailed histological characterization of *Klf6<sup>f/f</sup>Nkx3.1<sup>+/+</sup>* mice as old as 2 years failed to reveal any prostate tumors.<sup>7</sup> The lack of tumor phenotype in the *Klf6* mutant mice could be due to compensa-

tions/redundancy with other *Klf* family members. It is also possible that loss of *Klf6* might not be sufficient to initiate prostate tumorigenesis in the mouse and that loss/mutation of additional tumor suppressors might be required.

*Acknowledgments*—We thank Leisa Johnson, Mallika Singh, Hua Tian, and Zhenyu Gu for critical discussions. We also thank Margaret Fuentes, Christine Olsson, and Luz Orellana for assistance with the animal colony, Allison Bruce with Graphics, Jeffrey Eastham-Ander- son for MetaMorph analysis of *BMP4* *in situ* hybridization signal, and Howard Stern for his assistance with some histopathological review.

<sup>7</sup> C. C. Leow, B. Wang, J. Ross, S. M. Chan, J. Zha, R. A. D. Carano, G. Frantz, M. M. Shen, F. J. de Sauvage, and W.-Q. Gao, unpublished observations.



## REFERENCES

- Bieker, J. J. (2001) *J. Biol. Chem.* **276**, 34355–34358
- Huber, T. L., Perkins, A. C., Deconinck, A. E., Chan, F. Y., Mead, P. E., and Zon, L. I. (2001) *Curr. Biol.* **11**, 1456–1461
- Laub, F., Aldabe, R., Friedrich, V., Jr., Ohnishi, S., Yoshida, T., and Ramirez, F. (2001) *Dev. Biol.* **233**, 305–318
- Oates, A. C., Pratt, S. J., Vail, B., Yan, Y. I., Ho, R. K., Johnson, S. L., Postlethwait, J. H., and Zon, L. I. (2001) *Blood* **98**, 1792–1801
- Zhao, W., Hisamuddin, I. M., Nandan, M. O., Babbitt, B. A., Lamb, N. E., and Yang, V. W. (2004) *Oncogene* **23**, 395–402
- Chen, C., Bhalala, H. V., Qiao, H., and Dong, J. T. (2002) *Oncogene* **21**, 6567–6572
- Narla, G., Heath, K. E., Reeves, H. L., Li, D., Giono, L. E., Kimmelman, A. C., Glucksmann, M. J., Narla, J., Eng, F. J., Chan, A. M., Ferrari, A. C., Martignetti, J. A., and Friedman, S. L. (2001) *Science* **294**, 2563–2566
- Reeves, H. L., Narla, G., Ogunbiyi, O., Haq, A. I., Katz, A., Benzeno, S., Hod, E., Harpaz, N., Goldberg, S., Tal-Kremer, S., Eng, F. J., Arthur, M. J., Martignetti, J. A., and Friedman, S. L. (2004) *Gastroenterology* **126**, 1090–1103
- Kimmelman, A. C., Qiao, R. F., Narla, G., Banno, A., Lau, N., Bos, P. D., Nuñez Rodriguez, N., Liang, B. C., Guha, A., Martignetti, J. A., Friedman, S. L., and Chan, A. M. (2004) *Oncogene* **23**, 5077–5083
- Ito, G., Uchiyama, M., Kondo, M., Mori, S., Usami, N., Maeda, O., Kawabe, T., Hasegawa, Y., Shimokata, K., and Sekido, Y. (2004) *Cancer Res.* **64**, 3838–3843
- Sugimura, Y., Cunha, G. R., and Donjacour, A. A. (1986) *Biol. Reprod.* **34**, 961–971
- Freestone, S. H., Marker, P., Grace, O. C., Tomlinson, D. C., Cunha, G. R., Harnden, P., and Thomson, A. A. (2003) *Dev. Biol.* **264**, 352–362
- Wang, B. E., Shou, J., Ross, S., Koeppen, H., De Sauvage, F. J., and Gao, W. Q. (2003) *J. Biol. Chem.* **278**, 18506–18513
- Berman, D. M., Desai, N., Wang, X., Karhadkar, S. S., Reynon, M., Abate-Shen, C., Beachy, P. A., and Shen, M. M. (2004) *Dev. Biol.* **267**, 387–398
- Lamm, M. L., Catbagan, W. S., Laciak, R. J., Barnett, D. H., Hebner, C. M., Gaffield, W., Walterhouse, D., Iannaccone, P., and Bushman, W. (2002) *Dev. Biol.* **249**, 349–366
- Thomson, A. A., and Cunha, G. R. (1999) *Development* **126**, 3693–3701
- Lamm, M. L., Podlasek, C. A., Barnett, D. H., Lee, J., Clemens, J. Q., Hebner, C. M., and Bushman, W. (2001) *Dev. Biol.* **232**, 301–314
- Wang, X. D., Leow, C. C., Zha, J., Tang, Z., Modrusan, Z., Radtke, F., Aguet, M., de Sauvage, F. J., and Gao, W. Q. (2006) *Dev. Biol.* **290**, 66–80
- Wang, B. E., Wang, X. D., Ernst, J. A., Polakis, P., and Gao, W. Q. (2008) *PLoS ONE* **3**, e2186
- Kuo, C. T., Veselits, M. L., Barton, K. P., Lu, M. M., Clendenin, C., and Leiden, J. M. (1997) *Genes Dev.* **11**, 2996–3006
- Nuez, B., Michalovich, D., Bygrave, A., Ploemacher, R., and Grosfeld, F. (1995) *Nature* **375**, 316–318
- Segre, J. A., Bauer, C., and Fuchs, E. (1999) *Nat. Genet.* **22**, 356–360
- Matsumoto, N., Kubo, A., Liu, H., Akita, K., Laub, F., Ramirez, F., Keller, G., and Friedman, S. L. (2006) *Blood* **107**, 1357–1365
- Deleted in proof
- Bhatia-Gaur, R., Donjacour, A. A., Scivolino, P. J., Kim, M., Desai, N., Young, P., Norton, C. R., Gridley, T., Cardiff, R. D., Cunha, G. R., Abate-Shen, C., and Shen, M. M. (1999) *Genes Dev.* **13**, 966–977
- Oro, A. E., and Higgins, K. (2003) *Dev. Biol.* **255**, 238–248
- Jubb, A. M., Pham, T. Q., Frantz, G. D., Peale, F. V. Jr., and Hillan, K. J. (2006) *Methods Mol Biol.* **326**, 255–264
- Lung, B., and Cunha, G. R. (1981) *Anat. Rec.* **199**, 73–88
- Shappell, S. B., Thomas, G. V., Roberts, R. L., Herbert, R., Ittmann, M. M., Rubin, M. A., Humphrey, P. A., Sundberg, J. P., Rozengurt, N., Barrios, R., Ward, J. M., and Cardiff, R. D. (2004) *Cancer Res.* **64**, 2270–2305
- Schneider, A., Brand, T., Zweigerdt, R., and Arnold, H. (2000) *Mech. Dev.* **95**, 163–174
- Cunha, G. R., and Donjacour, A. (1987) *Prog. Clin. Biol. Res.* **239**, 273–282
- Cunha, G. R. (1994) *Cancer* **74**, 1030–1044
- Hayward, S. W., Baskin, L. S., Haughney, P. C., Foster, B. A., Cunha, A. R., Dahiya, R., Prins, G. S., and Cunha, G. R. (1996) *Acta Anat. (Basel)* **155**, 94–103
- Nemeth, J. A., and Lee, C. (1996) *Prostate* **28**, 124–128
- Donjacour, A. A., and Cunha, G. R. (1993) *Endocrinology* **132**, 2342–2350
- Tanaka, M., Komuro, I., Inagaki, H., Jenkins, N. A., Copeland, N. G., and Izumo, S. (2000) *Dev. Dyn.* **219**, 248–260
- Pu, Y., Huang, L., and Prins, G. S. (2004) *Dev. Biol.* **273**, 257–275
- Ramallo-Santos, M., Melton, D. A., and McMahon, A. P. (2000) *Development* **127**, 2763–2772
- Madison, B. B., Braunstein, K., Kuizon, E., Portman, K., Qiao, X. T., and Gumucio, D. L. (2005) *Development* **132**, 279–289
- Turner, J., and Crossley, M. (1999) *Trends Biochem. Sci.* **24**, 236–240
- Perkins, A. C., Gaensler, K. M., and Orkin, S. H. (1996) *Proc. Natl. Acad. Sci. U.S.A.* **93**, 12267–12271
- Kuo, C. T., Veselits, M. L., and Leiden, J. M. (1997) *Science* **277**, 1986–1990
- Hertveldt, V., Louryan, S., van Reeth, T., Drèze, P., van Vooren, P., Szpirer, J., and Szpirer, C. (2008) *Dev. Dyn.* **237**, 883–892
- Fischer, E. A., Verpont, M. C., Garrett-Sinha, L. A., Ronco, P. M., and Rossert, J. A. (2001) *J. Am. Soc. Nephrol.* **12**, 726–735
- Cunha, G. R., and Lung, B. (1979) in *Accessory Glands of Male Reproductive Tract*, Ann Arbor Science, Ann Arbor, MI, Vol. 6, pp. 1–28
- Cunha, G. R., Alarid, E. T., Turner, T., Donjacour, A. A., Boutin, E. L., and Foster, B. A. (1992) *J. Androl.* **13**, 465–475
- Narla, G., Friedman, S. L., and Martignetti, J. A. (2003) *Am. J. Pathol.* **162**, 1047–1052